Erlotinib or Gefitinib

DRUG3 trials

Sponsors

Anhui Medical University, Sun Yat-sen University, Novartis Pharmaceuticals

Conditions

Carcinoma, Non-small Cell LungDrug ToxicityGastrointestinal CancersSelf Efficacy

Phase 2

High-Dose,Pulsatile Erlotinib/Gefitinib for Advanced NSCLC Patients After Failure of Standard Dose EGFR-TKIs

Anhui Medical UniversityDrug Toxicity, Self Efficacy

Start: 2013-10-31End: 2017-12-31Target: 20Updated: 2017-05-08

Phase 3

Phase III Study of Nazartinib (EGF816) Versus Erlotinib/Gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating Mutations

WithdrawnNCT03529084

Novartis PharmaceuticalsCarcinoma, Non-small Cell Lung

Start: 2018-07-24End: 2024-06-03Updated: 2019-11-22

Unknown Phase

A Pilot Study of Genomic Sequencing Guided Individualized Therapy in Gastrointestinal Cancers, GITIC Study

Sun Yat-sen UniversityGastrointestinal Cancers

Start: 2013-12-31End: 2017-12-31Target: 50Updated: 2016-08-30